{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T17:16:02Z","timestamp":1782753362014,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s12325-022-02376-y","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T09:03:37Z","timestamp":1671440617000},"page":"903-919","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5465-1648","authenticated-orcid":false,"given":"David","family":"Fox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9506-7539","authenticated-orcid":false,"given":"Tu My","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0648-7764","authenticated-orcid":false,"given":"Arpamas","family":"Seetasith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1902-905X","authenticated-orcid":false,"given":"Anisha M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0851-3516","authenticated-orcid":false,"given":"Susan T.","family":"Iannaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"issue":"5","key":"2376_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","volume":"11","author":"E Mercuri","year":"2012","unstructured":"Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012;11(5):443\u201352.","journal-title":"Lancet Neurol"},{"issue":"2","key":"2376_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s13311-014-0314-x","volume":"12","author":"MA Farrar","year":"2015","unstructured":"Farrar MA, Kiernan MC. The genetics of spinal muscular atrophy: progress and challenges. Neurotherapeutics. 2015;12(2):290\u2013302.","journal-title":"Neurotherapeutics"},{"issue":"7","key":"2376_CR3","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00415-017-8549-1","volume":"264","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, et\u00a0al. A multi-source approach to determine SMA incidence and research ready population. J Neurol. 2017;264(7):1465\u201373.","journal-title":"J Neurol"},{"issue":"1","key":"2376_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13023-017-0724-z","volume":"12","author":"C Lally","year":"2017","unstructured":"Lally C, et\u00a0al. Indirect estimation of the prevalence of spinal muscular atrophy type I, II, and III in the United States. Orphanet J Rare Dis. 2017;12(1):175.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2376_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, et\u00a0al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155\u201365.","journal-title":"Cell"},{"issue":"11","key":"2376_CR6","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","volume":"96","author":"CL Lorson","year":"1999","unstructured":"Lorson CL, et\u00a0al. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA. 1999;96(11):6307\u201311.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2376_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0960-8966(91)90052-T","volume":"1","author":"T Munsat","year":"1991","unstructured":"Munsat T. Workshop report: international SMA collaboration. Neuromuscul Disord. 1991;1:81.","journal-title":"Neuromuscul Disord"},{"issue":"5\u20136","key":"2376_CR8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","volume":"2","author":"TL Munsat","year":"1992","unstructured":"Munsat TL, Davies KE. International SMA consortium meeting (26\u201328 June 1992, Bonn, Germany). Neuromuscul Disord. 1992;2(5\u20136):423\u20138.","journal-title":"Neuromuscul Disord."},{"issue":"10","key":"2376_CR9","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.nmd.2017.05.011","volume":"27","author":"EF Tizzano","year":"2017","unstructured":"Tizzano EF, Finkel RS. Spinal muscular atrophy: a changing phenotype beyond the clinical trials. Neuromuscul Disord. 2017;27(10):883\u20139.","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"2376_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, et\u00a0al. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3):197\u2013207.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"2376_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, et\u00a0al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103\u201315.","journal-title":"Neuromuscul Disord"},{"key":"2376_CR12","unstructured":"European Medicines Agency. Spinraza. 2017 [06\/11\/20]; Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spinraza."},{"key":"2376_CR13","volume-title":"SPINRAZA\u00ae (nusinersen) [package insert]","author":"Food and Drug Administration","year":"2016","unstructured":"Food and Drug Administration. SPINRAZA\u00ae (nusinersen) [package insert]. Cambridge: Biogen Inc.; 2016."},{"key":"2376_CR14","unstructured":"Biogen. SPINRAZA\u00ae (nusinersen) [package insert]. 2019 [cited 2022 September]; Available from: https:\/\/www.spinraza.com\/PI."},{"key":"2376_CR15","unstructured":"Novartis. ZOLGENSMA\u00ae (onasemnogene abeparvovec-xioi) [package insert]. 2019 [cited 2022 September]; Available from: https:\/\/www.fda.gov\/media\/126109\/download."},{"key":"2376_CR16","unstructured":"European Medicines Agency. ZOLGENSMA\u00ae (onasemnogene abeparvovec-xioi). 2020 May [cited 2021 November]; Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma."},{"key":"2376_CR17","unstructured":"US Food and Drug Administration. EVRYSDI\u00ae Highlights of prescribing information. 2020 [cited 2022 September]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213535s000lbl.pdf."},{"key":"2376_CR18","unstructured":"European Medicines Agency. EVRYSDI: Summary of Product Characteristics. 2021 [cited 2021 July]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/evrysdi-epar-product-information_en.pdf."},{"issue":"3","key":"2376_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/14656566.2019.1704732","volume":"21","author":"S Ramdas","year":"2020","unstructured":"Ramdas S, Servais L. New treatments in spinal muscular atrophy: an overview of currently available data. Expert Opin Pharmacother. 2020;21(3):307\u201315.","journal-title":"Expert Opin Pharmacother"},{"key":"2376_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, et\u00a0al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625\u201335.","journal-title":"N Engl J Med"},{"issue":"2","key":"2376_CR21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamapediatrics.2017.4409","volume":"172","author":"AM Burgart","year":"2018","unstructured":"Burgart AM, et\u00a0al. Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy. JAMA Pediatr. 2018;172(2):188\u201392.","journal-title":"JAMA Pediatr"},{"issue":"20","key":"2376_CR22","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1212\/WNL.0000000000006502","volume":"91","author":"D Michelson","year":"2018","unstructured":"Michelson D, et\u00a0al. Evidence in focus: Nusinersen use in spinal muscular atrophy: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;91(20):923\u201333.","journal-title":"Neurology"},{"issue":"5","key":"2376_CR23","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1212\/CPJ.0000000000000718","volume":"9","author":"CD Zingariello","year":"2019","unstructured":"Zingariello CD, et\u00a0al. A multidisciplinary approach to dosing nusinersen for spinal muscular atrophy. Neurol Clin Pract. 2019;9(5):424\u201332.","journal-title":"Neurol Clin Pract"},{"issue":"5","key":"2376_CR24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3233\/JND-210768","volume":"9","author":"L Elman","year":"2022","unstructured":"Elman L, et\u00a0al. Real-world adherence to nusinersen in adults with spinal muscular atrophy in the US: a multi-site chart review study. J Neuromuscul Dis. 2022;9(5):655\u201360.","journal-title":"J Neuromuscul Dis"},{"issue":"12","key":"2376_CR25","doi-asserted-by":"publisher","first-page":"5809","DOI":"10.1007\/s12325-021-01938-w","volume":"38","author":"M Gauthier-Loiselle","year":"2021","unstructured":"Gauthier-Loiselle M, et\u00a0al. Nusinersen for spinal muscular atrophy in the United States: findings from a retrospective claims database analysis. Adv Ther. 2021;38(12):5809\u201328.","journal-title":"Adv Ther"},{"key":"2376_CR26","unstructured":"IQVIA PharMetrics\u00ae Plus. 2020 [28\/05\/2020 25\/01\/2022]; Available from: https:\/\/www.iqvia.com\/library\/fact-sheets\/iqvia-pharmetrics-plus."},{"issue":"2","key":"2376_CR27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3233\/JND-190387","volume":"6","author":"J Yong","year":"2019","unstructured":"Yong J, Moffett M, Lucas S. Implementing a global expanded access program (EAP) for infantile-onset spinal muscular atrophy (type I): understanding the imperative impact and challenges. J Neuromuscul Dis. 2019;6(2):227\u201331.","journal-title":"J Neuromuscul Dis"},{"issue":"7","key":"2376_CR28","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0883073815627882","volume":"31","author":"M Hache","year":"2016","unstructured":"Hache M, et\u00a0al. Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience. J Child Neurol. 2016;31(7):899\u2013906.","journal-title":"J Child Neurol"},{"issue":"5","key":"2376_CR29","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","volume":"73","author":"B Vrijens","year":"2012","unstructured":"Vrijens B, et\u00a0al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691\u2013705.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2376_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157769","volume":"11","author":"CI Coleman","year":"2016","unstructured":"Coleman CI, Tangirala M, Evers T. Treatment persistence and discontinuation with rivaroxaban, dabigatran, and warfarin for stroke prevention in patients with non-valvular atrial fibrillation in the United States. PLoS ONE. 2016;11(6):e0157769.","journal-title":"PLoS ONE"},{"issue":"11","key":"2376_CR31","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1111\/ene.15501","volume":"29","author":"JF Vazquez-Costa","year":"2022","unstructured":"Vazquez-Costa JF, et\u00a0al. Nusinersen in adult patients with 5q spinal muscular atrophy: a multicenter observational cohorts\u2019 study. Eur J Neurol. 2022;29(11):3337\u201346.","journal-title":"Eur J Neurol"},{"issue":"1","key":"2376_CR32","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ppul.25140","volume":"56","author":"M Lavie","year":"2021","unstructured":"Lavie M, et\u00a0al. Nusinersen for spinal muscular atrophy type 1: real-world respiratory experience. Pediatr Pulmonol. 2021;56(1):291\u20138.","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"2376_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker T, et\u00a0al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 2020;19(4):317\u201325.","journal-title":"Lancet Neurol"},{"key":"2376_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","volume":"39","author":"J Erdos","year":"2022","unstructured":"Erdos J, Wild C. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data. Eur J Paediatr Neurol. 2022;39:1\u201310.","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"2376_CR35","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1212\/CPJ.0000000000001033","volume":"11","author":"T Duong","year":"2021","unstructured":"Duong T, et\u00a0al. Nusinersen treatment in adults with spinal muscular atrophy. Neurol Clin Pract. 2021;11(3):e317\u201327.","journal-title":"Neurol Clin Pract"},{"issue":"1","key":"2376_CR36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13643-019-1014-8","volume":"8","author":"A Gast","year":"2019","unstructured":"Gast A, Mathes T. Medication adherence influencing factors-an (updated) overview of systematic reviews. Syst Rev. 2019;8(1):112.","journal-title":"Syst Rev"},{"key":"2376_CR37","unstructured":"Biogen. CADTH common drug review: clinical review report. Nusinersen (Spinraza). 2018."},{"issue":"1","key":"2376_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, et\u00a0al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014a literature review. Orphanet J Rare Dis. 2017;12(1):124.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2376_CR39","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883\u201391.","journal-title":"Ann Neurol"},{"key":"2376_CR40","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jpeds.2020.07.033","volume":"227","author":"A Jalali","year":"2020","unstructured":"Jalali A, et\u00a0al. Cost-effectiveness of nusinersen and universal newborn screening for spinal muscular atrophy. J Pediatr. 2020;227:274\u201380.","journal-title":"J Pediatr"},{"key":"2376_CR41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4088\/PCC.20m02625","volume":"22","author":"MS Chawa","year":"2020","unstructured":"Chawa MS, et\u00a0al. The impact of socioeconomic status, race\/ethnicity, and patient perceptions on medication adherence in depression treatment. Prim Care Companion CNS Disord. 2020;22(6):20m02625.","journal-title":"Prim Care Companion CNS Disord"},{"issue":"12","key":"2376_CR42","first-page":"e461","volume":"18","author":"D Scheurer","year":"2012","unstructured":"Scheurer D, et\u00a0al. Association between different types of social support and medication adherence. Am J Manag Care. 2012;18(12):e461\u20137.","journal-title":"Am J Manag Care"},{"issue":"16","key":"2376_CR43","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013148","volume":"8","author":"H Lee","year":"2019","unstructured":"Lee H, et\u00a0al. Combined effect of income and medication adherence on mortality in newly treated hypertension: nationwide study of 16 million person-years. J Am Heart Assoc. 2019;8(16): e013148.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"2376_CR44","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.nmd.2021.02.014","volume":"31","author":"D MacCannell","year":"2021","unstructured":"MacCannell D, et\u00a0al. Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen. Neuromuscul Disord. 2021;31(4):310\u20138.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"2376_CR45","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40263-022-00899-0","volume":"36","author":"D MacCannell","year":"2022","unstructured":"MacCannell D, et\u00a0al. Restoration of nusinersen levels following treatment interruption in people with spinal muscular atrophy: simulations based on a population pharmacokinetic model. CNS Drugs. 2022;36(2):181\u201390.","journal-title":"CNS Drugs"},{"issue":"4","key":"2376_CR46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/BPB.0000000000000632","volume":"28","author":"L Labianca","year":"2019","unstructured":"Labianca L, Weinstein SL. Scoliosis and spinal muscular atrophy in the new world of medical therapy: providing lumbar access for intrathecal treatment in patients previously treated or undergoing spinal instrumentation and fusion. J Pediatr Orthop B. 2019;28(4):393\u20136.","journal-title":"J Pediatr Orthop B"},{"issue":"suppl 1","key":"2376_CR47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40273-021-01092-9","volume":"40","author":"SH Lo","year":"2022","unstructured":"Lo SH, et\u00a0al. Preferences and utilities for treatment attributes in type 2 and non-ambulatory type 3 spinal muscular atrophy in the United Kingdom. Pharmacoeconomics. 2022;40(suppl 1):91\u2013102.","journal-title":"Pharmacoeconomics"},{"key":"2376_CR48","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-020-01667-3","volume":"16","author":"A Monette","year":"2021","unstructured":"Monette A, et\u00a0al. Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet J Rare Dis. 2021;16:36.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2376_CR49","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/13696998.2019.1646263","volume":"23","author":"M Droege","year":"2020","unstructured":"Droege M, et\u00a0al. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment. J Med Econ. 2020;23(1):70\u20139.","journal-title":"J Med Econ"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02376-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02376-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02376-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T07:24:30Z","timestamp":1678087470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02376-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["2376"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02376-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]},"assertion":[{"value":"9 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}